Neomed Management is an international venture capital investment firm focused on the healthcare industry.
Business Model:
Revenue: $12.5M
Employees: 2-10
Address: 6440 Norwalk Rd
City: Medina
State: OH
Zip: 44256
Country: US
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date. NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries. NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America. From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies. NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Contact Phone:
+13307224400
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2014 | Wilson Therapeutics | Series B | 40M |
5/2017 | Axonics Modulation Technologies | Series C | 0 |
3/2016 | 4Tech | Series B | 0 |
10/2015 | Sequana Medical | Series C | 0 |
4/2003 | Oxxon Therapeutics | Venture Round | 0 |
9/2017 | Sonendo | Private Equity Round | 0 |
8/2011 | Vessix Vascular | Series B | 0 |
2/2020 | JenaValve Technology | Venture Round | 50M |
6/2012 | Sonendo | Series C | 0 |
8/2015 | Avitide | Series C | 7.6M |
11/2012 | Endosense | Series C | 40.3M |
4/2014 | Sequana Medical | Series C | 26.1M |
1/2020 | Sonendo | Venture Round | 85M |
10/2005 | Kuros Biosciences | Post-IPO Equity | 0 |
1/2005 | Kuros Biosciences | Post-IPO Equity | 0 |
6/2013 | Sonendo | Series C | 0 |
12/2016 | Sonendo | Series E | 0 |
3/2014 | Axonics Modulation Technologies | Series A | 32.6M |
10/2009 | Endosense | Series B | 0 |
2/2014 | InDex Pharmaceuticals | Venture Round | 20M |
6/2009 | Clavis Pharma | Post-IPO Equity | 20M |
10/2018 | Sequana Medical | Series D | 0 |
3/2021 | Oxular | Series B | 37M |
12/2008 | Diagnoplex | Series A | 8.3M |
6/2017 | Avitide | Equity | 12M |
3/2011 | Sequana Medical | Series B | 25.5M |
1/2015 | Genkyotex | Post-IPO Equity | 0 |
9/2013 | Arsanis | Series B | 20M |
1/2007 | Sequana Medical | Series A | - |
12/2015 | Axonics Modulation Technologies | Series B | 0 |
8/2014 | Sonendo | Series D | 0 |
6/2007 | PregLem | Series A | 26M |
1/2014 | TopiVert | Venture Round | 7.4M |
10/2010 | Vessix Vascular | Venture Round | 4.7M |
6/2008 | Creabilis | Series A | 31.4M |
12/2007 | PregLem | Series B | 32.2M |
11/2005 | Endosense | Series A | 19.8M |
11/2003 | Thommen Medical | Series C | 0 |
6/2013 | Diagnoplex | Venture Round | 1.4M |
10/2001 | Aderis Pharmaceuticals | Series D | 0 |
10/2006 | Santhera Pharmaceuticals | Series C | 0 |
12/2006 | Xanthus Pharmaceuticals | Series B | 0 |
4/2014 | JenaValve Technology | Series C | 0 |
8/2015 | JenaValve Technology | Series C | 26.5M |
2/2020 | JenaValve Technology | Series D | 0 |
1/2007 | Novexel | Series B | 65M |
7/2013 | JenaValve Technology | Series C | 62.5M |
6/2010 | JenaValve Technology | Series B | 22.7M |
11/2013 | Endosense | Series C | 41.2M |
3/2021 | Oxular | Series B | 0 |
2/2020 | JenaValve Technology | Series D | 0 |
1/2020 | Sonendo | Venture Round | 0 |
10/2018 | Sequana Medical | Series D | 0 |
9/2017 | Sonendo | Private Equity Round | 0 |
6/2017 | Avitide | Series E | 0 |
5/2017 | Axonics Modulation Technologies | Series C | 0 |
12/2016 | Sonendo | Series E | 0 |
3/2016 | 4Tech | Series B | 0 |
12/2015 | Axonics Modulation Technologies | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|